Home › Acute Myeloid Leukemia › California › Orange
Acute Myeloid Leukemia clinical trials in Orange, CA
12 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Children's Hospital of Orange County, Orange
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
RecruitingPhase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Children's Hospital of Orange County, Orange
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- Children's Hospital of Orange County Main Campus - Orange, Orange
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- University of California, Irvine, Orange
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RecruitingPhase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RecruitingPhase 4
- UCI Irvine Health, Orange
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Children's Hospital of Orange County (CHOC), Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX86 studies
- New York City, NY51 studies
- Boston, MA45 studies
- Baldwin Park, CA40 studies
- Seattle, WA40 studies
- Columbus, OH34 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Tampa, FL29 studies
- Atlanta, GA29 studies
- Chicago, IL27 studies
- Portland, OR25 studies
Other studies in Orange
- Non-Small Cell Lung Cancer25 studies
- Metastatic Cancer20 studies
- Colorectal Cancer16 studies
- Ovarian Cancer16 studies
- Pancreatic Cancer15 studies
- Lung Cancer14 studies
- Cancer (all types)14 studies
- Melanoma14 studies
- Prostate Cancer14 studies
- Breast Cancer14 studies
- Liver Cancer (Hepatocellular Carcinoma)14 studies
- Stomach Cancer13 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.